Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease


Although paclitaxel-based devices which demonstrated improved outcomes in the treatment of lower-extremity peripheral artery disease (PAD) have been used worldwide, Katsanos et al. reported a systematic review and summary-level meta-analysis of RCTs in which application of paclitaxel-based devices in the femoropopliteal artery was associated with an increased mortality risk. The purpose of this study was to describe the safety of endovascular therapy (EVT) using paclitaxel-coated stents for femoropopliteal disease by evaluating the mortality risk compared with patients treated with paclitaxel-free devices. A retrospective, multicenter, non-randomized study examined 481 de-novo symptomatic PAD patients treated in 13 Japanese medical centers from January 2011 to December 2015. The risk of all-cause mortality was analyzed between the 65 patients treated with a paclitaxel-coated stent (PTX-coated group) and 416 patients treated with an uncoated balloon or bare nitinol stent (PTX-free group). Overall survival of the PTX-coated group and the PTX-free group were compared after propensity score matching. The 2-year overall survival estimates were 87.7% in the PTX-coated group vs 88.7% in the PTX-free group. There were no significant differences in the mortality risk between the groups through a full follow-up of 2 years (p = 0.80). The multivariate cox proportional hazards model identified three significant predictors of mortality; age (HR, 1.08; 95% CI, 1.03–1.13; p = 0.002), hemodialysis (HR, 3.16; 95% CI, 1.34–7.42; p = 0.008), and albumin (g/dl) (HR, 0.46; 95% CI, 0.25–0.85; p = 0.01).

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. 1.

    Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, et al. IN.PACT SFA trial investigators: durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–38.

    Article  Google Scholar 

  2. 2.

    Rosenfield K, Jaff MR, White CJ, White CJ, Rocha-Singh K, Mena-Hurtado C, et al. LEVANT 2 investigators: trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–53.

    CAS  Article  Google Scholar 

  3. 3.

    Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.

    Article  Google Scholar 

  4. 4.

    Takahara M, Iida O, Soga Y, Kawasaki D, Fujihara M. Mortality risk of femoropopliteal paclitaxel-coated devices remains inconclusive. Cardiovasc Interv Ther. 2019;34(2):194–5.

    Article  Google Scholar 

  5. 5.

    Holden A, Varcoe RL, Jaff MR, Schneider PA, Tepe G, Zeller T. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26(4):467–70.

    Article  Google Scholar 

  6. 6.

    Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group: inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5-67.

    Article  Google Scholar 

  7. 7.

    Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212-220.

    Article  Google Scholar 

  8. 8.

    Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. IN.PACT SFA Trial Investigators: Drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN. PACT SFA randomized trial. Circulation. 2015;131(5):495–502.

    CAS  Article  Google Scholar 

  9. 9.

    Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, et al. RANGER SFA investigators: 12-Month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11(10):934–41.

    Article  Google Scholar 

  10. 10.

    Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.

    Article  Google Scholar 

  11. 11.

    Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, et al. MDT-2113 SFA Japan Investigators: drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019;93(4):664–72.

    Article  Google Scholar 

  12. 12.

    Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clin Pharmacokinet. 2018;57(1):7–19.

    CAS  Article  Google Scholar 

  13. 13.

    Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX stents—evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011;22(5):603–10.

    Article  Google Scholar 

  14. 14.

    Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis. J Am Coll Cardiol. 2019;73(20):2550–63.

    Article  Google Scholar 

  15. 15.

    Gray WA, Jaff MR, Parikh SA, Ansel GM, Brodmann M, Krishnan P, et al. Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the ILLUMENATE clinical program at 3 years. Circulation. 2019;140(14):1145–55.

    CAS  Article  Google Scholar 

  16. 16.

    Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Zilver PTX Investigators: durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472–83.

    CAS  Article  Google Scholar 

  17. 17.

    Katsuki T, Takahara M, Soga Y, Okamoto S, Iida O, Fujihara M, et al. Mortality risk following application of a paclitaxel-coated stent in femoropopliteal lesions. J Endovasc Ther. 2019;26(5):593–9.

    Article  Google Scholar 

  18. 18.

    Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52(3):608–15.

    Article  Google Scholar 

  19. 19.

    Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial. 2015;19(6):540–74.

    CAS  Article  Google Scholar 

  20. 20.

    Nakano M, Hirano K, Iida O, Soga Y, Kawasaki D, Suzuki K, et al. Prognosis of critical limb ischemia in hemodialysis patients after isolated infrapopliteal balloon angioplasty: results from the Japan below-the-knee artery treatment (J-BEAT) registry. J Endovasc Ther. 2013;20(1):113–24.

    Article  Google Scholar 

  21. 21.

    Ancion A, Allepaerts S, Oury C, Gori AS, Pierard LA, Lancellotti P. Serum albumin level and hospital mortality in acute non-ischemic heart failure. ESC Heart Fail. 2017;4(2):138–45.

    Article  Google Scholar 

  22. 22.

    Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. The prognostic impact of malnutrition in patients with severely decompensated acute heart failure, as assessed using the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score. Heart Vessels. 2018;33(2):134–44.

    Article  Google Scholar 

  23. 23.

    Gonzalez L, Kassem M, Owora AH, Seligson MT, Richards CY, Monita MM, et al. Frailty and biomarkers of frailty predict outcome in veterans after open and endovascular revascularization. J Surg Res. 2019;243:539–52.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Michinao Tan.

Ethics declarations

Conflict of interest

The authors declare no association with any individual, company, or organization having a vested interest in the subject matter/products mentioned in this article.

Human rights and ethical standards

This study was approved by the ethics committee of each hospital and written informed consents were obtained from patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tan, M., Urasawa, K., Haraguchi, T. et al. Mortality risk after use of a paclitaxel-coated stent in femoropopliteal peripheral artery disease. Cardiovasc Interv and Ther (2021).

Download citation


  • Drug-coated stent
  • Endovascular therapy
  • Mortality
  • Paclitaxel
  • Peripheral artery disease